TEN BEST READINGS ON T-CELL LYMPHOID MALIGNANCIES
Thomas P. Loughran, Jr, MD H. Lee Moffitt Cancer Center
& Research Institute
The ten best articles in the medical literature relating
to T-cell lymphoid malignancies are reviewed here.
Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and
laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78:3269-3274.
Matutes and colleagues describe the clinical and laboratory findings in the largest
series of patients with T-prolymphocytic leukemia. The aggressive nature of this disease
is highlighted.
Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell
prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997;15: 2667-2672.
This article describes exciting results in the treatment of T-PLL with humanized CD52
monoclonal antibody (MAb) (CAMPATH-1H). Sixty percent of patients treated with CD52 MAb
achieved complete remission compared to only 12% with deoxycoformycin. The possible role
of autologous stem cell transplantation in first remission is discussed.
Franchini G. Molecular mechanisms of human T-cell leukemia/
lymphotropic virus type I infection. Blood. 1995;86:3619-3639.
The pathogenesis of HTLV-I infection in causing human disease is reviewed. Molecular
concepts are summarized, and the transactivating properties of the HTLV-I pX gene are
emphasized.
Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary
syndrome. Blood. 1996;88: 2385-2409.
The clinicopathologic features of cutaneous T-cell lymphomas are comprehensively
reviewed. This is an excellent overview of the basic biology as well as treatment options
in cutaneous T-cell lymphomas.
Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood.
1993;82:1-14.
The current classification of clonal LGL diseases into T-cell and NK-cell LGL leukemias
was initially proposed in this review. The clinical and immunologic characteristics of
these diseases are discussed.
Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic
T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell
origin. Blood. 1996;88:4265-4274.
The clinicopathologic features of eight patients with hepatosplenic T-cell lymphoma are
described. An aggressive clinical course is typical. The authors conclude that this
disease is a distinct entity involving clonal proliferation of gamma delta cytotoxic
T-cells.
Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat
Med. 1996;2:317-322.
The authors describe establishment of an ELISA for detection of Fas ligand in human
sera. A variety of hematologic malignancies were screened using this test. Elevated levels
of Fas ligand were found only in sera from patients with LGL leukemias/lymphomas.
Hoyer JD, Ross CW, Li CY, et al. True T-cell chronic lymphocytic
leukemia: a morphologic and immunophenotypic study of 25 cases. Blood.
1995;86:1163-1169.
Twenty-five cases of true T-CLL were collected over a 15-year period at a single
institution. The leukemic cells in these cases were distinct from T-PLL and LGL. Most
cases were CD4+. These patients were characterized as having an aggressive disease that
was refractory to treatment.
Virgilio L, Grazia Narducci M, Isobe M, et al. Identification of
the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA.
1994;91:12530-12534.
This paper reports the cloning of the TCL1 gene on chromosome 14q32.1. This gene is
implicated in the development of chronic T-cell leukemias, particularly T-prolymphocytic
leukemia and those occurring in patients with ataxia telangiectasia.
Armus S, Keyes B, Cahill C, et al. Photopheresis for the
treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 1990;23:898-902.
The authors explore the use of extracorporeal chemotherapy
(photopheresis) in patients with cutaneous T-cell lymphoma. They conclude that
photopheresis is an effective modality in combination with adjunctive therapy for
erythroderma, for extensive patch/ plaque disease, and for some patients with tumor-stage
disease.
Back to Cancer Control Journal Volume 5
Number 1